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Abstract: The prognosis of some of the most prevalent conditions seems to be intricately related 
to myriad risk factors, largely modiﬁ  able, but often leading to irreversible complications when 
left unmanaged. This study exempliﬁ  es the multidisciplinary approach necessary, to success-
fully control diabetic retinopathy, one of the leading complications of diabetes, and to discuss 
promising therapies. Based on a Medline Ovid database search, we present a clinical and eco-
nomic review of the evidence on the epidemiology and risk factors of diabetic retinopathy, its 
prognosis and economic implications. Among adults aged 20–74, diabetic retinopathy (DR) is 
the most frequent cause of blindness. However, in both types 1 and 2 DM, improved glycemic 
control reduces the development and progression of DR. Risk factors of DR include duration 
of diabetes, pregnancy, renal disease, age, smoking, alcohol, hyperlipidemia and antioxidants. 
A number of drugs may play a role in DR therapy in the coming few years; eg, somatostatin 
agonists (sandostatin), corticosteroids (triamcinolone, dexamethasone, ﬂ  uocinolone), vascular 
endothelial growth factor inhibitors (pegaptanib, ranibizumab), hyaluronidase and plasmin 
enzyme. Whether these therapies have a clinically signiﬁ  cant impact on DR progression how-
ever, remains to be seen.
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In a most recent era in medicine history, we have moved from the thrust to treat acute 
conditions, to the need to prevent and manage chronic diseases, which top the list for 
high morbidity and mortality conditions. The prognosis of some of the most prevalent 
conditions seems to be intricately related to myriad risk factors, largely modiﬁ  able, 
but often leading to irreversible complications when left unmanaged. The study we 
present herein exempliﬁ  es the multidisciplinary approach, often necessary, to suc-
cessfully control such conditions. We speciﬁ  cally focus on diabetic retinopathy, one 
of the leading complications of diabetes, because of its high public health impact, 
high morbidity, impact on quality of life, and general societal welfare. In an effort to 
better inform prevention and treatment, we have conducted a clinical and economic 
review of the evidence on the epidemiology and risk factors of diabetic retinopathy, 
its prognosis and economic implications.
Medline search using Ovid database was done. The search strategy was made by 
using “focus function” with term diabetic retinopathy combined with prevalence, 
incidence, risk factors, prevention, cost-effectiveness and prognosis. The results then 
were limited to humans and English language. In some cases where the yield was larger 
than 50 articles, the yield was limited to the period between 2000 and 2006.
Deﬁ  nition and classiﬁ  cation
Diabetic retinopathy (DR) is one of the micro-vascular complications of diabetes 
mellitus (DM). It is a progressive sight threatening disease that affects retinal vascu-
latures (AAO 2003). One of the widely accepted classiﬁ  cations of DR is the American 
Academy of Ophthalmology’s classiﬁ  cation. According to this classiﬁ  cation DR is Clinical Ophthalmology 2007:1(3) 260
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classiﬁ  ed as: non-proliferative DR (NPDR) and proliferative 
DR (PDR). NPDR is the earliest stage of DR. In NPDR, 
retinal vasculatures are characterized by microaneurysm, 
intraretinal hemorrhage and cotton weed spots. NPDR is 
further classiﬁ  ed as mild, moderate and severe according the 
degree of Severity (AAO 2003; Goldman 2004) (Table 1). 
As DR progresses, a gradual closure of retinal vasculatures 
occurs. As a result of these closures, areas supplied by the 
affected blood vessels become ischemic. Manifestations of 
retinal ischemia include venous abnormalities such as loops, 
beadings, intraretinal microvascular abnormalities (IRMA), 
increased retinal hemorrhage and exudation that lead to 
severe and extensive leakage (AAO 2003). Severe NPDR 
occurs when these signs go beyond certain deﬁ  ned thresholds. 
Patients with severe NPDR should consider scatter laser 
photocoagulation as a possible treatment for their case (AAO 
2003). PDR is the advanced stage of DR. It is characterized by 
the formation of new vessels at the optic disc (NVD) or new 
vessels elsewhere in the retina (NVE) (AAO 2003). These 
new vessels are weak and can bleed easily, causing vitreous 
hemorrhage. Fibrosis and contraction of these new vessels 
may lead to complications such as vitreoretinal traction, 
bands, retinal tears and rhegmatogenous retinal detachment 
(AAO 2003). PDR progresses to the highest stage of severity 
when one of the following scenarios happens: new vessels 
on or within 1 disc diameter of the optic disc equaling or 
exceeding standard photograph 10A (about 1/4 to 1/3 disc 
area), with or without vitreous or preretinal hemorrhage; or 
vitreous and/or preretinal hemorrhage accompanied by new 
vessels either on the optic disc less than standard photograph 
10A or new vessels elsewhere equaling or exceeding 1/2 disc 
area (AAO 2003). Predisposing risk factors for high risk PDR 
include increased severity of retinopathy, decreased visual 
acuity, higher glycosylated hemoglobin, history of diabetic 
neuropathy, lower hematocrit, elevated triglycerides, lower 
serum albumin, and, in persons with mild to moderate non-
proliferative retinopathy, younger age (or type 1 diabetes) 
(Davis 1997). High risk PDR is the major risk factor for 
severe visual loss or vitrectomy (Davis 1997).
The central region of the retina is known as the macula 
which contains the fovea. The fovea is located at the center 
of the macula and is responsible for central vision. When 
microaneurysms or microvascular hemorrhages occur around 
the macula or the fovea macular lesions and exudates are 
developed. The term diabetic maculopathy (DM) is used to 
describe the macular abnormalities due to diabetes. Diabetic 
maculopathy can be classiﬁ  ed to diabetic macular edema 
(DME) and clinically signiﬁ  cant macular edema (CSME) 
(Fong 1997). DME is deﬁ  ned as retinal thickening within 
1 disc diameter of the center of the macula and/or hard 
exudates (Fong 1997). CSME occurs if any of the following 
ﬁ  ndings were recognized: (1) retinal thickening within 500 
μm of the center of the macula; (2) hard, yellow exudates 
within 500 μm of the center of the macula with adjacent 
retinal thickening; and (3) at least 1 disc area of retinal 
thickening, any part of which is within 1 disc diameter of the 
center of the fovea (Fong 1997). CSME is a major cause for 
sight-threatening retinopathy and central vision loss.
Epidemiology
Among adults aged 20–74, diabetic retinopathy (DR) is the 
most frequent cause of blindness (ADA 2006). As a sight-
threatening retinopathy, there are 12,000–24,000 new cases 
of blindness caused by DR each year (ADA 2006). It is 
estimated that more than 60% of patients with type 2 DM and 
nearly all patients with type 1 DM will have retinopathy by 
Table 1 International clinical diabetic retinopathy disease severity scale
Proposed disease severity level  Findings observable upon dilated opthalmoscopy
No apparent retinopathy  No abnormalities
Mild nonproliferative diabetic retinopathy  Microaneurysms only
Moderate nonproliferative diabetic retinopathy  More than just microaneurysms but less than severe NPDR
Severe nonproliferative diabetic retinopathy  Any of the following:
  •  More than 20 intraretinal hemorrhages in each of four quadrants
  • Deﬁ  ne venous beading in two or more quadrants
  •  Prominent IRMA in one or more quadrants
  And no signs of proliferative retinopathy
Proliferative diabetic retinopathy  One or both of the following:
  • Neovascularization
  • Vitreous/preretinal  hemorrhage
Abbreviations: IRMA, intraretinal microvascular abnormalities; NPDR, nonproliferative diabetic retinopathy.Clinical Ophthalmology 2007:1(3) 261
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the second decade of diagnosis (Klein 1984a, 1984b; Fong 
2004. The prevalence of retinopathy at diagnosis of type1 
DM is 0%–3%, while in type 2 DM the prevalence of DR is 
6.7%–30.2% (Williams 2004; RCO 2005). The Wisconsin 
Epidemiological Study of Diabetic Retinopathy (WESDR) 
reported 74% prevalence at 9–10 years duration and 95% 
at 13–14 years duration of type 1 DM (Klein 1984a). The 
Wisconsin Diabetes Registry Study (WDRS) studied the 
prevalence and severity of DR in a population-based cohort 
followed for 4–14 years during the period between 1990 and 
2002. In this study, the investigators recruited 474 diabetic 
patients from the same counties of Wisconsin where patients 
were recruited to participate in the WESDR trial 20 years 
earlier. They found that the prevalence of DR increased 
with the duration of diabetes; from 6% in the fourth year of 
diagnosis to 73% in the 14th year (LeCaire 2006). The ﬁ  nd-
ing was consistent across all ages and highest among adults 
20 years of age or older. Additionally, WDRS reported 47% 
prevalence at 9–10 years duration and 73% at 13–14 years 
duration of DM. WDRS and other studies ﬁ  ndings indicate 
that the prevalence of DR decreased over the last 20 years 
(Younis 2002, 2003; LeCaire 2006). This ﬁ  nding can be 
explained by the huge changes in diabetes care since 1980. 
Within the Medicare population, one study followed 20,325 
patients from 1991 to 1999. At the end of the ninth year, 
10,476 patients were analyzed and investigators found that 
the prevalence of DR among patients with diabetes mellitus 
increased from 6.9% to 17.4% (Lee 2003).
In WESDR, the 4-year incidence of DR within type 2 
DM patients was 59%. (Klein 1990). In patient with type 2 
DM, the 4-year incidence of any DR was 34% within insulin 
users and 47.4% within non-insulin users. In the same 
study, progression of retinopathy was more frequent 
within type 1 DM and type 2 insulin users – 41% and 34% 
respectively – than within type 2 DM non-insulin users 
(25%). Ten percent of type 1 DM patients progressed to PDR 
over 4 years. In type 2 DM patients, 7% of insulin users, ver-
sus only 2% non-users, progressed to PDR over 4 years.
It is very important to interpret prevalence and incidence 
studies with the understanding that many factors can inﬂ  u-
ence both of them. For instance, Williams and his colleagues 
(2004) did a systematic review on the prevalence and the 
incidence of DR and macular edema. They stated that the 
prevalence of blindness and visual impairment is declining 
despite the fact that the incidence of DR remains constant. 
The reasons behind this phenomenon are better control of 
glucose, blood pressure as well as lipids. In addition, the 
improvement in screening methods, laser treatment as well 
as patient’s awareness of their disease contributed further 
to this phenomenon (Williams 2004). Therefore, while the 
incidence of DR remains constant over time the prevalence of 
DR increases due to the aforementioned reasons. In the other 
hand, many of the clinical trials that addressed prevalence 
and incidence of DR were clinic based rather than popula-
tion based. Therefore, disease frequency and severity may 
be overestimated since patients with long standing diabetes 
complications may refer to specialists for eye examinations 
rather than receiving a community based eye examination.
Prevention of diabetic retinopathy
Prevention of DR falls into two steps. First, preventing the 
development of DR. However, once the patient is diagnosed 
with DR the goal is to slow down the progression the disease 
and prevent the development of sight-threatening retinopathy 
that eventually will lead to partial visual loss or blindness. 
Many risk factors are believed to play an important role in 
this process. While some of them can be modiﬁ  ed others 
can’t. Maintaining modiﬁ  able risk factors within normal 
ranges such as blood pressure and glycosylated hemoglobin 
(HbA1c) has shown to reduce the development and progres-
sion of DR. Other risk factors of DR include duration of 
diabetes, pregnancy, renal disease, age, smoking, alcohol, 
hyperlipidemia and antioxidants. In 2005, the Royal College 
of Ophthalmologists (RCO) published new treatment guide-
lines for DR. The following section discusses the suggested 
risk factors and the RCO observations and recommendations 
each one of them (RCO 2005).
Modiﬁ  able risk factors
Glycemic control and glycosylated 
hemoglobin
In both types 1 and 2 DM, improved glycemic control (mea-
sured by HbA1c), reduces the development and progression 
of DR. The advantages of improved glycemic control apply 
to all ages and both genders. The Diabetes Control and 
Complications Trial (DCCT) observational study (DCCT 
1995) reported that the higher the HbA1c and the shorter 
the duration of diabetes at entry, the greater the beneﬁ  t of 
intensive therapy and improved glycemic control. In the trial, 
a 10% lower HbA1c was associated with a 44% lower risk. 
In another study, patients without retinopathy at baseline 
(DCCT primary cohort) were assigned to either good or poor 
metabolic control. Among the 153 DCCT patients with “good 
metabolic control” (mean HbA1c = 6.87%), three-step change 
retinopathy developed in (9.8%), while (90%) remained free 
of retinopathy. On the other hand, among the 166 patients Clinical Ophthalmology 2007:1(3) 262
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with “poor metabolic control” (mean HbA1c = 9.49%), the 
complication developed in (57%) (Zhang 2001).
The United Kingdom Prospective Diabetes Study 
(UKPDS) is another important study that examined the effect 
of intensive therapy versus conventional therapy on the devel-
opment of macrovascular and microvascular complications 
in 3867 newly diagnosed patient with type 2 DM. The inten-
sive therapy resulted in statistically signiﬁ  cant reduction in 
HbA1c comparing to conventional therapy. (7% vs 7.9). This 
intensive glycemic control conferred a 34% risk reduction in 
the development of DR. Furthermore, there was a clinically 
signiﬁ  cant reduction in the need for retinal photocoagulation 
with intensive therapy verses conventional therapy (7.9 vs 11 
events per 1000 patients – year p = 0.003). Additionally, the 
need for cataract extraction was signiﬁ  cantly reduced with 
intensive therapy over conventional therapy (5.6 vs 7.4 events 
per 1000 patients – year p = 0.046) (UKPDS 1998a).
Therefore, in patients with diabetes or patients with 
HbA1c higher than 7%, the following recommendation 
should be applied: (1) patients should understand HbA1c, 
what it means, and how to lower it; (2) patients should be 
encouraged to lower their HbA1c, and be given the neces-
sary treatment and support to allow this; (3) if retinopathy 
develops, HbA1c should be maintained at a level below 7% 
but caution should be exercised if a high risk retinopathy 
is present; (4) patients should understand that potential 
temporary worsening of retinopathy may occur with diabetes 
control, but long term beneﬁ  ts should be stressed; and ﬁ  nally 
(5) establishment of local links between ophthalmologists 
and physicians should be stressed, in order to smooth the 
progress of early referral for management of risk factors in 
progressive cases.
Blood pressure
In type 1 DM patients, treatment of hypertension with ACEIs 
resulted in a 23% reduction in the progression of DR. In addi-
tion, in type 2 DM patients, the analyses of the UKPDS trial 
showed that control of blood pressure reduces the progression 
of DR and visual acuity deterioration by 34% and 47% with 
tight control of blood pressure (144/82) and (152/87) respec-
tively (UKPDS 1998b). The results from this study and other 
studies suggested that the beneﬁ  cial effect of anti-hypertensive 
treatment and the deleterious effect of increased blood pres-
sure are immediate and require regular measurement of blood 
pressure. Information regarding the best antihypertensive regi-
men was not conclusive. These observations have led to the 
following recommendations: (1) blood pressure measurement 
methodology should be correct and casual clinic measurements 
should be avoided; (2) even a small reduction in blood pres-
sure, especially systolic blood pressure is considered beneﬁ  -
cial; (3) patients should understand their blood pressure, what 
it means, and how to lower it; (4) patients should be counseled 
about the potential harm if they stop their therapy and their 
blood pressure increases; (5) patients should be encouraged to 
lower their blood pressure, and be given the necessary treat-
ment and support to allow this; (6) regular measurement of 
blood pressure, to ensure continuing control is recommended; 
(7) if retinopathy has already developed, systolic blood pres-
sure should be below 130 mmHg; and (8) an ACE inhibitor or 
angiotensin receptor antagonist antihypertensive drug may be 
considered since it provides additional beneﬁ  t, over and above 
its blood pressure lowering effect.
Tobacco and alcohol use
Discontinuation of smoking is recommended for reducing the 
development of other complications of diabetes. However, 
it appears that cigarette smoking is not a risk factor for the 
development or progression of DR. Information regarding 
the role of alcohol in worsening or improving of DR is 
inconclusive.
Aspirin and thrombolytics
The use of thrombolytics doesn’t increase the risk of retinal 
hemorrhage in reperfusion therapy of myocardial ischemia. 
Furthermore, aspirin therapy neither reduces nor increases the 
risk of developing retinopathy or retinal hemorrhage. There-
fore, retinopathy should not be a contraindication for aspirin 
therapy or thrombolytic therapy for myocardial infarction.
Hypercholesterolemia
Although some studies showed a correlation between high 
cholesterol blood levels and risk of retinopathy, others failed 
to ﬁ  nd any correlation. In addition, no randomized control 
trial has shown any beneﬁ  t of lowering cholesterol blood 
level in terms of retinopathy risk reduction.
Antioxidants
One study about the efﬁ  cacy of antioxidants in preventing 
the development of DR showed no beneﬁ  t regarding their 
use. The study showed that vitamin E was associated with 
increased severity of DR among those not taking insulin. 
In addition, among those taking insulin, increased intake of 
beta-carotene was associated with a risk for severity of DR 
(Mayer-Davis 1998). Therefore, the role of antioxidants in 
developing or worsening DR has been investigated; however 
there is no evidence of effectiveness.Clinical Ophthalmology 2007:1(3) 263
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Non-modiﬁ  able
Pregnancy
Most pregnant patients with mild to moderate retinopathy 
will not experience any changes during pregnancy. However, 
a small, unpredictable group may progress to PDR and remain 
at risk for a year after delivery. Unfortunately, there is lim-
ited evidence that pre-gestational counseling is beneﬁ  cial, in 
terms of deterioration of retinopathy during pregnancy. The 
Panel recommended that pre-pregnancy counseling should 
be provided to the patients; especially for improvement in 
glycemic control. In addition, screening should be done 
before conception, in each trimester and between 3 and 9 
months post-natally.
Renal disease
Some studies have shown an increased risk of retinopathy 
worsening especially in the macula. Hemodialysis can be 
a better explanation for the observed worsening being a 
stronger associated risk factor. However, treatment of renal 
disease was associated with an improvement in retinopathy 
and a beneﬁ  cial response to treatment.
Furthermore, patients with developing nephropathy – 
determined by the presences of microalbuminuria – have 
increased blood pressure that can be the cause of higher 
risk of retinopathy. Therefore, the panel recommended more 
frequent regular supervision of retinopathy in patients with 
established renal dysfunction. In addition, aggressive blood 
pressure control is essential to reducing the rate of progres-
sion of both retinopathy and nephropathy.
Age and duration of diabetes
In Both type 1 and 2 DM, duration of diabetes is associated 
with higher incidence and prevalence of DR. Older patients 
with diabetes have a greater risk of visual impairment.
Screening for diabetic retinopathy
Since the early stages of retinopathy are asymptomatic, any 
loss of vision can’t be restored. Laser photocoagulation is 
effective at slowing down the progression of the disease but 
not at restoring lost vision (Fong 2004). Therefore, different 
guidelines stressed the importance of early detection of DR 
(AAO 2003; RCO 2005).
Medications and aggravation of 
diabetic retinopathy
Whether certain medications can trigger the development of 
DR or not, is still unclear. The evidence on the presence of 
a relationship between certain antidiabetic agents and dia-
betic retinopathy is inconclusive. One study followed up 30 
patients who used either pioglitazone, rosiglitazone, or both 
at different times, and who had both lower extremity edema 
and macular edema. The discontinuation of glitazones in 
eleven of these patients led to a reduction of macular edema 
in 4 patients in <3 months and a total of 8 over two years. 
(Ryan 2006) In another observational study that was done 
to assess the association of insulin lispro with the develop-
ment and progression of DR in 12 pregnant women, insulin 
lispro was not associated with any risk of DR. (Buchbinder 
2000). The fact that these studies were observational with a 
very small sample size, makes the results inconclusive and 
hardly generalizable.
Ocular complications associated 
with diabetic retinopathy
Diabetic retinopathy is associated with many complications 
such as retinal detachment, rubeosis iridis and rubeotic 
glaucoma. In PDR, contraction and condensation of the 
vitreous gel in association with hemorrhage and ﬁ  brosis 
lead to tractional retinal detachment. Rubeosis iridis takes 
place when advanced retinal ischemia leads to the growth 
of new vessels on the iris. Rubeotic glaucoma occurs when 
the aqueous ﬂ  uid drainage rout in the anterior chamber of 
the eye blocked by the formation of ﬁ  brotic tissues around 
it. Rarely, optic neuropathy may occur (RCO 2005).
Cost beneﬁ  t analyses
The medical and economic effects of applying accepted 
methods for controlling DR among type 1 DM patients 
have been predicted using computer simulation models. The 
investigators of one model designed a model using the fol-
lowing published reports: Recommendations for screening 
of DR from the Public Health Committee of the American 
Academy of Ophthalmology. Treatment recommendations 
and treatment efﬁ  cacy from the reports of the Diabetic 
Retinopathy Study (DRS) and the Early Treatment Diabetic 
Retinopathy Study (ETDRS) and costs of screening and 
treatment from published Medicare reimbursement data. 
The model predicted that over a 60 years period, 72% of 
type 1 patients eventually will develop PDR requiring pan-
retinal photocoagulation and that 42% will develop macular 
edema. When treatments are delivered according to clinical 
trial recommendations, the model predicts a cost of $966 
per person-year of vision saved from PDR and $1,118 per 
person-year of central acuity saved from macular edema. 
These costs are lower than the costs of one year of Social Clinical Ophthalmology 2007:1(3) 264
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Security Disability for those disabled by vision loss due 
sight – threatening retinopathy (Javitt 1989). Furthermore, 
the model predicts that if all patients received appropriate 
eye care, the predicted savings would exceed 167.0 million 
and 79,236 person-years-sights (Javitt 1991).
Another computer simulated model was used to evalu-
ate the cost-effectiveness of screening and treatment for 
diabetic retinopathy from a societal viewpoint. Computation 
was performed on three subpopulations formed by patients 
with younger onset diabetes (age at diagnosis less than 30) 
of 5 years or more duration, with older onset diabetes (age 
at diagnosis greater than or equal to 30) who are taking 
insulin, and with older onset diabetes not taking insulin. 
The investigators found that annual examination with 
mydriatic fundus photography as a screening program to a 
cohort of 1,000 diabetics from the younger onset popula-
tion who have been diagnosed at least 5 years and who are 
currently not receiving care might save 319 sight years over 
the lifetime of the cohort. The program will save 62 sight 
years in an older onset cohort who are taking insulin, and 
21 sight years in the older onset population not taking 
insulin. (Dasbach 1991).
Prognosis
Prognosis of DR depends on the stage of the disease and 
the availability of treatment. Around 5%–10% of diabetic 
patients with normal retinal exam will develop diabetic 
retinopathy within one year. Therefore, initial dilated and 
comprehensive eye examinations should be done within 3–5 
years after diagnosis of type 1 DM and with the diagnosis of 
type 2 DM. The examination helps to detect early DR where 
maintaining glucose level and blood pressure within the nor-
mal recommended ranges is considered the main available 
therapeutic modality for mild to moderate NPDR without 
macular edema. For instance, the DCCT showed 75% and 
50% reduction in the development and progression of DR 
after 3 years of intensive treatment to reduce blood glucose 
respectively (AAO 2003).
Early Treatment Diabetic Retinopathy Study (ETDRS) 
recommendations are considered the main gold standard 
practice for the treatment of advanced stages of DR. 
According to ETDRS recommendations, patients with 
severe NPDR, non-high risk PDR, high risk PDR should 
be treated with scatter photocoagulation also known as pan-
retinal photocoagulation. Early treatment of severe NPDR 
and non-high risk PDR before the progression to high risk 
PDR – the sight-threatening retinopathy – was associated 
with 50% reduction in the risk of blindness and vitrectomy 
comparing with treatment deferral until high risk PDR is 
developed (AAO 2003; Bhavsar 2006).
If the patient develops tractional retinal detachment or 
vitreous hemorrhage that hinder this procedure, then vitrec-
tomy should be considered.
Currently a number of clinical trials are investigating 
drugs with different mechanism of actions for the treatment 
of DR. For instance, ruboxistaurin (RBX) is a new drug that 
inhibits the β-isoform of protein kinase C (PKC) enzyme 
which is believed to play an important role in the develop-
ment of microvascular complications of diabetes. Animal 
models demonstrated that PKC mediates the increase in 
retinal vascular permeability and neovascularization shown 
in DR. Additionally, PKC has shown to mediate the changes 
in retinal blood ﬂ  ow in diabetic patients (PKC-DRS 2005). 
Therefore, RBX was suggested to be a good candidate for 
prevention of DR as well as delay the progression of already 
developed DR. Recently published in march 2007, a multi-
center, double-blind, randomized, placebo-controlled study 
was investigating the effect of ruboxistaurin verses placebo in 
686 patients with diabetic macular edema DME. The primary 
outcomes was the progression of DME and/or the application 
of focal/grid laser photocoagulation. After thirty months, 
the results didn’t show any statistical signiﬁ  cant difference 
in this composite primary endpoint. However, considering 
progression of DME alone, the daily administration of RBX 
32 mg may delay progression of DME to a sight-threatening 
stage. In terms of side effects, RBX was well tolerated except 
for ﬁ  rst-degree atrioventricular block, asthma, and dysuria. 
These side effects didn’t appear in other 6–12 months RBX 
trials (PKC-DMES 2007).
It is very important to take in consideration that the inclu-
sion criteria was very speciﬁ  c and included eyes with DME 
farther than 300 μm from the center of the macula, mild to 
moderately severe nonproliferative diabetic retinopathy, a 
visual acuity of 20/32 or better, and no prior laser photoco-
agulation for diabetic retinopathy or DME. Therefore, the 
generalizability of these results to all patients with macular 
edema or DR can be an issue.
Another double-masked, placebo-controlled, parallel, 
randomized, single-center clinical study was done to evaluate 
the effect of oral administration of RBX on the mean retinal 
circulation time (RCT) and retinal blood ﬂ  ow (RBF). The 
study included 28 patients with type 1 or 2 DM and no or 
very mild DR. The results showed a statistically signiﬁ  cant 
reduction in the diabetes-induced increased RCT and RBF. 
This may suggest a potential role for RBX in early preven-
tion of DR (Aiello 2006). However, whether this reduction Clinical Ophthalmology 2007:1(3) 265
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in RCT and RBF is sufﬁ  cient to reduce the incidence of DR 
is another question that needs further investigation.
There are many other drugs that may play a role in DR 
therapy in coming few years such as somatostatin agonists 
(sandostatin), corticosteroids (triamcinolone, dexametha-
sone, fluocinolone), vascular endothelial growth factor 
inhibitors (pegaptanib, ranibizumab), hyaluronidase and 
plasmin enzyme (AAO 2003; Bhavsar 2006). Whether these 
future therapies will have a clinically signiﬁ  cant impact on 
the development and/or the progression of the disease and 
subsequently the prognosis of the disease is unknown. This 
question will open a new horizon for future research.
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